<SEC-DOCUMENT>0001213900-25-112861.txt : 20251120
<SEC-HEADER>0001213900-25-112861.hdr.sgml : 20251120
<ACCEPTANCE-DATETIME>20251120083027
ACCESSION NUMBER:		0001213900-25-112861
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251120
FILED AS OF DATE:		20251120
DATE AS OF CHANGE:		20251120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-AUTO DEALERS & GASOLINE STATIONS [5500]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		251501119

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0266570-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of November 2025 (Report No. 2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F
&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 20, 2025, SciSparc Ltd. (the &ldquo;Company&rdquo;)
issued a press release titled &ldquo;SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine
for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression.&rdquo; A copy of this press release is furnished herewith as Exhibit
99.1 to this Report of Foreign Private Issuer on Form 6-K and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Report of Foreign Private
Issuer on Form 6-K is incorporated by reference into the Company&rsquo;s registration statements on Form F-3 (File Nos.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000101376225002218/ea0235372-f3_scisparc.htm">333-286099</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023083494/ea187529-f3_scisparc.htm">333-275305</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999-f3_scisparc.htm">333-269839</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022037966/ea162219-f3_scisparcltd.htm">333-266047</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm">333-233417</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm">333-248670</A>&nbsp;and&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023018886/ea174796-posam_scisparc.htm">333-255408</A>)
and on Form S-8 (File Nos.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390024028880/ea0203015-s8_scisparc.htm">333-278437</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A>&nbsp;and&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390025035801/ea0239224-s8_scisparc.htm">333-286791</A>)
filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 9%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea026657001ex99-1_scisparc.htm">Press release issued by SciSparc Ltd. titled &ldquo;SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression.&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SciSparc Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 20, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea026657001ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: NEUROTHERA LABS ANNOUNCES ISRAELI PATENT APPLICATION IN COLLABORATION WITH CLEARMIND MEDICINE FOR NOVEL NON-HALLUCINOGENIC NEUROPLASTOGEN TREATMENT FOR DEPRESSION."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 120px; width: 120px"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">SciSparc: Neurothera
Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment
for Depression</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">TEL AVIV, Israel,
Nov. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (&ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;), today announced that
NeuroThera Labs Inc. (TSXV: NTLX) (&ldquo;NeuroThera&rdquo;), a clinical-stage pharmaceutical company focused on developing novel treatments
for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration
with Clearmind Medicine Inc. by filing an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane
(MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), targeting depression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">The patent
application results from the ongoing collaboration between Neurothera and Clearmind Medicine Inc. (Nasdaq: CMND). This therapy targets
depression treatment using the combination of MEAI and PEA. According to the&nbsp;World
Health Organization&nbsp;data from August 2025, major depressive disorder affects, approximately 332 million people worldwide are
living with depression. This represents an estimated 5.7% of adults globally (higher among women at 6.9% compared to 4.6% in men), and
it remains one of the leading causes of disability worldwide, contributing significantly to the global burden of disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">This new filing
further expands the joint intellectual property portfolio developed through the collaboration. To date, 13 patents have been filed through
the collaboration, focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction,
obesity and weight loss, and depression. Preclinical data supports MEAI&rsquo;s efficacy in mitigating addictive behaviors while preserving
normal natural reward pathways.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>About SciSparc
Ltd. (Nasdaq: SPRC):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">The Company,
through its majority-owned subsidiary Neurothera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc&rsquo;s focus
is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company,
together with its majority-owned subsidiary Neurothera Labs Inc., are currently engaged in the following drug development programs based
on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer&rsquo;s disease and agitation;
and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through Neurothera Labs Inc., also owns a controlling interest
in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>About Neurothera
Labs Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">Neurothera
Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and
other underserved health conditions through collaborations and innovative combinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>Forward-Looking
Statements:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">This press
release contains forward-looking statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation
Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential
benefits and advantages of the new patent filing, that this therapy has the potential to address depression treatment, and that the patents
that have been filed through the collaboration with Clearmind Medicine Inc. have the potential to address alcohol use disorder, cocaine
addiction, obesity and weight loss, and depression. Because such statements deal with future events and are based on SciSparc&rsquo;s current
expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ
materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied
in this press release are subject to other risks and uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo;
in SciSparc&rsquo;s Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities
and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or
circumstances or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">Investor Contact:<BR>
IR@scisparc.com<BR>
Tel: +972-3-6167055</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $H 2@# 2(  A$! Q$!_\0
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M#GARQ)"C]UHN@A(025#,%38Q&64$9KOZ "BBB@ HHHH **** "BBB@ HHHH
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M_P 0O'.C>&=3U#2U8JVL!92&",5X8?*Z@.I*D&OKVOXF/^#CG_@A_P#MW_\
M!2S]KSX4?%[]EGPI\.=:\(>%O@Q'X)U:[\6_$31?!>I#Q+'KFOZT<0SQMYZA
M9D42AO+#DJ6PQV '])?_  ]L_P""8W_1^/[,O_AU?"/_ ,=KIOA__P %+/V
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M_":P,31Z_P#$SXI^-,B/P];>$HRCHOSB25_-9$DB1V .@_X(R_M(?%?]I/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'\=O@%J?A_X4?%7P+X]U:UTL^,/[1O-.\/:]%K<FT>4H#DPE,JRLRY W*&+
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MU=58HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MP=6T?2]>T^?2];TRPU&QNES=66IVB:CI[\<@I* G'7G;CL1WT;>T@LXA;VD$
M%O H)\BW4+UX./NC] >,9/2BB@"[1110 4444 %%%% !1110 4444 %%%% !
*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
